These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7329958)

  • 41. [A micromethod for preparing concentrated leukocyte suspensions].
    Guliaeva EA; Filiushina ZG
    Lab Delo; 1986; (12):753-4. PubMed ID: 2434724
    [No Abstract]   [Full Text] [Related]  

  • 42. Improved preparation of leukocytes for chemiluminescent study of human phagocytic leukocyte-generated reactive oxygen species.
    Saniabadi AR; Nakano M
    J Biolumin Chemilumin; 1993; 8(4):207-13. PubMed ID: 8396845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Introduction: timing of leukodepletion of blood products.
    Heaton A
    Semin Hematol; 1991 Jul; 28(3 Suppl 5):1-2. PubMed ID: 1925635
    [No Abstract]   [Full Text] [Related]  

  • 44. Improvement in isolation of human peripheral blood leukocyte subpopulations: application in diagnosing human cytomegalovirus infection in bone marrow transplant patients.
    Behzad-Behbahani A; Yaghobi R; Sabahi F; Rostaei MH; Alborzi A
    Exp Clin Transplant; 2005 Jun; 3(1):316-9. PubMed ID: 15989676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Present status of the use of fresh whole blood].
    Fujii H
    Rinsho Byori; 1991 Mar; Suppl 88():402-9. PubMed ID: 1856991
    [No Abstract]   [Full Text] [Related]  

  • 46. Interpretation of atypical patterns encountered when using a flow cytometry-based method to detect residual leukocytes in leukoreduced red blood cell components.
    Janatpour K; Paglieroni TG; Schuller L; Foley K; Rizzardo T; Holland PV
    Cytometry; 2002 Oct; 50(5):254-60. PubMed ID: 12360575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Editorial: Component transfusion therapy.
    Br Med J; 1974 Aug; 3(5930):544. PubMed ID: 4412928
    [No Abstract]   [Full Text] [Related]  

  • 48. [New ways of improving the solutions for preservation of the erythrocyte suspension at positive temperature].
    Ginzburg FG; Sukhova AG; Dantser NA
    Probl Gematol Pereliv Krovi; 1967 Apr; 12(4):3-9. PubMed ID: 6073297
    [No Abstract]   [Full Text] [Related]  

  • 49. Leucodepletion and immune response mechanisms.
    Semple JW
    Vox Sang; 2004 Jul; 87 Suppl 2():136-8. PubMed ID: 15209898
    [No Abstract]   [Full Text] [Related]  

  • 50. [Progress and problems in transfusion medicine].
    Ohto H
    Rinsho Ketsueki; 2011 Oct; 52(10):1544-9. PubMed ID: 21971231
    [No Abstract]   [Full Text] [Related]  

  • 51. [Blood component therapy (author's transl)].
    Kretschmer V
    Anasth Intensivther Notfallmed; 1980 Jun; 15(3):189-200. PubMed ID: 7468950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Biological properties of cryopreserved leukocytes and their clinical application].
    Agranenko VA; Faĭnshteĭn FE; Ermolovich SV; Khoroshko ND; Abezgauz NN
    Probl Gematol Pereliv Krovi; 1982 Apr; 27(4):6-10. PubMed ID: 6954458
    [No Abstract]   [Full Text] [Related]  

  • 53. Improved erythrocyte sedimentation and leucocyte recovery with Dextran T500.
    Antrum RM; Solomkin JS
    Med Lab Sci; 1986 Jan; 43(1):44-7. PubMed ID: 2421125
    [No Abstract]   [Full Text] [Related]  

  • 54. [Preparation of leukocyte poor blood. Comparison of 5 different methods].
    Rasmussen NJ; Grunnet N
    Ugeskr Laeger; 1981 Nov; 143(45):2974-7. PubMed ID: 7330990
    [No Abstract]   [Full Text] [Related]  

  • 55. [The possibility of blood component therapy in Croatia (author's transl)].
    Grgicević D; Bozović I; Pende B
    Lijec Vjesn; 1981; 103(2-3):119-22. PubMed ID: 7311696
    [No Abstract]   [Full Text] [Related]  

  • 56. Storage times of whole blood and of buffy coat determine leucocyte degradation in platelet concentrates.
    Karger R; Kretschmer V
    Vox Sang; 2005 Oct; 89(3):170; author reply 171. PubMed ID: 16146511
    [No Abstract]   [Full Text] [Related]  

  • 57. Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers.
    Seghatchian J
    Transfus Apher Sci; 2006 Feb; 34(1):125-30. PubMed ID: 16376152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparative characteristics of an erythrocyte suspension with different plasma-substitute solutions].
    Poliakova LP; Agranenko VA; Suvorova IA; Golubeva VL; Borzova LV
    Probl Gematol Pereliv Krovi; 1980 Jan; 25(1):11-5. PubMed ID: 7367394
    [No Abstract]   [Full Text] [Related]  

  • 59. Rationale and strategy for utilization of available blood in transfusion practice--an overview.
    Khurana SK; Thergaonkar A; Dhupia JS; Verma SK; Talib VH
    Indian J Pathol Microbiol; 1996 Oct; 39(4):343-54. PubMed ID: 9009494
    [No Abstract]   [Full Text] [Related]  

  • 60. Leukocyte-poor red blood cells (washed) prevent transfusion reactions.
    Palermo GJ; Bove JR
    Conn Med; 1981 Dec; 45(12):753-4. PubMed ID: 7307514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.